Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert Says
April 19th 2023Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.